FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review

  • ID: 4285130
  • SWOT Analysis
  • 42 pages
  • GlobalData
1 of 5
FibroGen Inc (FGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody developed to treat duchenne muscular dystrophy, idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. Its roxadustat is supported by extensive clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. The company conducts research and development in the fields of connective tissue growth factor and hypoxia-inducible factor. FibroGen is headquartered in San Francisco, California, the US.

FibroGen Inc Key Recent Developments

May 09, 2018: FibroGen Reports First Quarter 2018 Financial Results
Feb 27, 2018: FibroGen Announces Fourth Quarter and Full Year 2017 Financial Results
Nov 08, 2017: FibroGen Reports Third Quarter 2017 Financial Results
Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors
Aug 07, 2017: FibroGen Reports Second Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Section 1 - About the Company
  • FibroGen Inc - Key Facts
  • FibroGen Inc - Key Employees
  • FibroGen Inc - Key Employee Biographies
  • FibroGen Inc - Major Products and Services
  • FibroGen Inc - History
  • FibroGen Inc - Company Statement
  • FibroGen Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • FibroGen Inc - Business Description
  • R&D Overview
  • FibroGen Inc - Corporate Strategy
  • FibroGen Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • FibroGen Inc - Strengths
  • FibroGen Inc - Weaknesses
  • FibroGen Inc - Opportunities
  • FibroGen Inc - Threats
  • FibroGen Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • FibroGen Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2018: FibroGen Reports First Quarter 2018 Financial Results
  • Nov 08, 2017: FibroGen Reports Third Quarter 2017 Financial Results
  • Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors
  • Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors
  • Aug 07, 2017: FibroGen Reports Second Quarter 2017 Financial Results
  • May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results
  • Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • FibroGen Inc, Key Facts
  • FibroGen Inc, Key Employees
  • FibroGen Inc, Key Employee Biographies
  • FibroGen Inc, Major Products and Services
  • FibroGen Inc, History
  • FibroGen Inc, Subsidiaries
  • FibroGen Inc, Key Competitors
  • FibroGen Inc, Ratios based on current share price
  • FibroGen Inc, Annual Ratios
  • FibroGen Inc, Annual Ratios (Cont...1)
  • FibroGen Inc, Interim Ratios
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • FibroGen Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • FibroGen Inc, Performance Chart (2013 - 2017)
  • FibroGen Inc, Ratio Charts
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Accelovance Inc
  • Achillion Pharmaceuticals Inc
  • Allergan Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll